Evidence map›Paper›PMID 33758881›Full record

ArticlemedRxiv : the preprint server for health sciences2021

Characterizing the COVID-19 illness experience to inform the study of post-acute sequelae and recovery: a qualitative study.

Edda I Santiago-Rodriguez, Andres Maiorana, Michael J Peluso, Rebecca Hoh, Viva Tai, Emily A Fehrman, Yanel Hernandez, Leonel Torres, Matthew A Spinelli, Monica Gandhi and 5 more

Open access · greenAbstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Edda I Santiago-RodriguezCenter for AIDS Prevention Studies, University of California, San Francisco, San Francisco, CA.
Andres MaioranaCenter for AIDS Prevention Studies, University of California, San Francisco, San Francisco, CA.
Michael J PelusoDivision of HIV, ID and Global Medicine, University of California, San Francisco, San Francisco, CA.
Rebecca HohDivision of HIV, ID and Global Medicine, University of California, San Francisco, San Francisco, CA.
Viva TaiDivision of HIV, ID and Global Medicine, University of California, San Francisco, San Francisco, CA.
Emily A FehrmanDivision of HIV, ID and Global Medicine, University of California, San Francisco, San Francisco, CA.
Yanel HernandezDivision of HIV, ID and Global Medicine, University of California, San Francisco, San Francisco, CA.
Leonel TorresDivision of HIV, ID and Global Medicine, University of California, San Francisco, San Francisco, CA.
Matthew A SpinelliDivision of HIV, ID and Global Medicine, University of California, San Francisco, San Francisco, CA.
Monica GandhiDivision of HIV, ID and Global Medicine, University of California, San Francisco, San Francisco, CA.
J Daniel KellyDivision of HIV, ID and Global Medicine, University of California, San Francisco, San Francisco, CA.
Jeffrey N MartinDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA.
Timothy J HenrichDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA.
Steven G DeeksDivision of Experimental Medicine, University of California, San Francisco, San Francisco, CA.
John A SaucedaCenter for AIDS Prevention Studies, University of California, San Francisco, San Francisco, CA.
University of California, San Francisco · US

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Monica Gandhi · 1988 to 2026
$93.6M
TRAINEESHIPS IN AIDS PREVENTION STUDIEST32MH019105 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Carol Suzanne Camlin, Glenn-Milo Santos · 1989 to 2026
$15.3M
Training in HIV Translational ResearchT32AI060530 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Diane V Havlir · 2005 to 2026
$6.4M
Targeting Non Viral Markers of HIV PersistenceR01AI141003 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HENRICH, TIMOTHY JENSEN · 2018 to 2022
$4.9M
Evaluation of the Interplay between HIV and COVID-19 in a large urban safety-net HIV clinicR01AI158013 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GANDHI, MONICA, SPINELLI, MATTHEW A. · 2020 to 2023
$3.1M
Understanding the epidemiology and natural history of unrecognized Ebola virus infectionK23AI146268 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KELLY, JOHN DANIEL · 2019 to 2022
$748k
NIAID NIH HHS K23 AI146268NIAID NIH HHS P30 AI027763NIAID NIH HHS R01 AI141003NIAID NIH HHS R01 AI158013NIAID NIH HHS T32 AI060530NIMH NIH HHS T32 MH019105
6 · The paper itself

Abstract

We aimed to characterize the variability in the illness experience and recovery process from COVID-19. We conducted in-depth individual interviews with participants enrolled in the Long-term Immunological Impact of Novel Coronavirus (LIINC) cohort study in San Francisco, California from June through October of 2020. Participants were adults who had a previously confirmed positive SARV-CoV-2 nucleic acid amplification test result, had recovered or were recovering from acute infection, and underwent serial evaluations at our clinical research center. We purposefully sampled 24 English- and Spanish-speaking adults with asymptomatic, mild and severe symptomatic infection, including those who were hospitalized, and those with HIV co-infection. Half of our sample (50.0%) identified as Latinx/Hispanic and most of the participants were men (62.5%). We used thematic analysis to characterize the illness experience, recovery process, and mental health impact of experiencing COVID-19 and present clinical data for each participant. Emergent themes were: (1) across symptom profiles and severity, experiencing COVID-19 was associated with psychological distress, (2) among participants with symptomatic infection, the illness experience was characterized by uncertainty in terms of managing symptoms and recovery, and (3) despite wide-ranging illness experiences, participants shared many common characteristics, including health information-seeking behavior facilitated by access to medical care, and uncertainty regarding the course of their illness and recovery. COVID-19 was associated with elevated levels of psychological distress, regardless of symptoms.

Indexed as

coronavirusCOVID-19mental healthpost-acute sequelae of SARS-CoV-2 (PASC)recovering from COVID-19SARS-Cov-2

Identifiers

PMID33758881
PMCPMC7987040
OpenAlexW3137897687

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.